Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Abivax American Depositary Shares ABVX

Healthcare Biotechnology
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The... see more

Recent & Breaking News (NDAQ:ABVX)

    Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

    GlobeNewswire November 19, 2024

    Abivax presents third quarter 2024 key financial information

    GlobeNewswire November 14, 2024

    Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

    GlobeNewswire November 13, 2024

    Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

    GlobeNewswire October 7, 2024

    Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

    GlobeNewswire October 3, 2024

    Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

    GlobeNewswire October 3, 2024

    Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

    GlobeNewswire September 26, 2024

    Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

    GlobeNewswire September 25, 2024

    Abivax presents first-half 2024 financial results

    GlobeNewswire September 9, 2024

    Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

    GlobeNewswire August 6, 2024

    Abivax Provides Operational and Key Program Update

    GlobeNewswire July 15, 2024

    Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

    GlobeNewswire June 4, 2024

    Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

    Accesswire February 13, 2024